HIB & Diabetes

[Guest guest]

HIB & Diabetes

http://www.vaccination.org.uk/vaccines/diabetes1.html

CHILDHOOD IMMUNISATION AND DIABETES MELLITUS

Taken from: New Zealand MedicalJournal 24/5/96, p195.

We have demonstrated that immunisation starting at birth can prevent

the development of diabetes in rodents and is associated with a

decreased incidence of diabetes in humans while immunisation starting

after 6 weeks is associated with an increased risk of developing

insulin dependent diabetes in humans and rodents. After a

presentation of our data we were asked to evaluate the effect of a

recent hepatitis B immunisation programme in New Zealand on the

development of insulin dependent diabetes. We found a large epidemic

of diabetes, 60% increase, occurred in New Zealand following this

immunisation programme and believe the most likely explanation is

that the immunisation programme caused the diabetes epidemic.

A massive hepatitis B immunisation programme was started in New

Zealand in 1988. The programme was phased in so initially children 5

or under were immunised but the programme was extended over the next

few years to include all children under 16. The acceptance rates were

estimated to be above 70% (personal communication, Dr H Nicholls,

Ministry of Health). Children born in 1988 and 1989 were immunised at

birth, however children born before or after this time were immunised

after 6 weeks of age. Based on our previous data we would thus expect

the immunisation programme to increase the risk of diabetes in all

groups except those immunised at birth, thus an epidemic of diabetes

would be expected. The only diabetes registry that exists in New

Zealand, to the best of our knowledge, is in Christchurch which has

prospectively followed a group of approximately 100,000 individuals

under 20 since 1982. The incidence of diabetes in this group prior to

the hepatitis B immunisation programme (1982-7) was 11.2

cases/100,000/year (range 7.6-13.2) while the incidence of diabetes

following the immunisation programme (1989-91) was 18.2

cases/100,000/year (range 16.4-21.7) (p=0.001). Data has not yet been

published on the incidence of diabetes after 1991.

The hepatitisB vaccines have been noted in the package inserts and

Physicians Desk Reference to cause several autoimmune diseases, and

the FDA has gone on record that the hepatitis B vaccines cause the

autoimmune disease alopecia (US FDA internet home page). The

hepatitis B vaccine, as well as other vaccines, can potentially

induce insulin dependent diabetes through the release of interferons

since interferons have been implicated in causing autoimmunity

including insulin dependent diabetes. Based on this mechanism and our

early finding that diabetes epidemics have followed the widespread

use of the Haemophilus influenza B vaccine we expect a second

epidemic of diabetes to follow the Haemophilus influenza B

immunisation programme that was started in New Zealand in 1993/4. We

hope that we can enlist the support of researchers in New Zealand to

help us perform cohort epidemiology studies to substantiate our

initial observations.

J Barthelow Classen, Classen Immunotherapies Inc, Baltimore, USA

**********

http://vaccines.net/hemophil.htm (see charts at webpage)

Hemophilus Influenza B Vaccine

See data from Finland proving the vaccine causes diabetes

1. The graph below shows that the annual incidence of diabetes rose

drastically after hemophilus immunization began in Finland.

HiB Finland 01a.wmf (15024 bytes)

2. The graph below shows that the annual incidence of diabetes rose

drastically after hemophilus immunization began in Pittsburgh.

hib-pittsburgh 0-4 1994.jpg (164248 bytes)

3. The graph below shows that the annual incidence of diabetes rose

in England after the hemophilus vaccine became widely utilized in the

UK (Reference British Medical Journal 315:713-716, 1997). The

hemophilus vaccine was started in October of 1992 in most regions

however large studies were conducted in some regions about 2 years earlier.

HiB UK 01a.WMF (21260 bytes)

Discussion

The incidence of IDDM rose drastically in Finland after

immunization with the Hemophilus vaccine began. A trial of Hemophilus

influenza conjugate vaccine was initiated in January 1986 and

included 114,000 children born between October 1,1985 and August

31,1987. Based on the results of the trial the Hemophilus influenza

vaccine became part of the standard vaccine schedule in Finland

starting in January of 1988 (Eskola, Kayhty, Takalaet al.1990). The

widespread use of the Hemophilus influenza vaccine in 1986 was

followed by a 62% rise (16 cases/100,000 children to 29.2

cases/100,000) in the incidence of diabetes in the 0-4 age group

between the years 1980-1982 and 1990-1992 (Tuomilehto, Virtala,

Karvonenet al.1995; Classen,DC & Classen, 1997). The cumulative

incidence of IDDM in 0-4 year olds in Finland rose 65 cases/100,000

between 1980-1982 and 1990-1992 as calculated from the rise in the

annual incidence in children under 5 from 16 cases/100,000 to 29.2

cases/100,000 immunized: ((29.2-16)x5)). An extra 50 cases of

IDDM/100,000 children immunized represents about an extra 2,000 cases

of IDDM a year in the US based on an annual birth cohort of 4 million

children.

Drastic rises in the incidence of IDDM have also been

reported in the US and the UK after the introduction of the HiB

vaccine. An epidemic of diabetes in the 0-4 age group occurred during

the years 1985-1989 in Allegheny county (Dokheel, 1993) at a time

when the Hemophilus influenza vaccine was being incorporated into the

immunization schedule. The FDA approved the Hemophilus influenza

polysaccharide vaccine in 1985 and the conjugated vaccine in 1987.

The vaccine was widely administered to children in Allegheny county,

a study of its efficacy performed in Allegheny county showed that

about 36% of children, chosen as controls, were immunized with the

vaccine between August of 1985 and July of 1987 (Shapiro, ,

Waldet al.1988). The annual incidence of IDDM in 0-4 year olds living

in Allegheny county rose 60% from the years 1980-1984 (10

cases/100,000) to 1985-1989 (16 cases/100,000). The incidence of

diabetes in 0-4 year olds had been consistently below 10

cases/100,000 from 1965-1984 (Dokheel, 1993). The incidence of IDDM

also rose 33% in the UK starting in 1994 (Gardner, Bingley, Sawtellet

al.1997) following the introduction of the HiB vaccine in the UK in

October, 1992 (Brewster, 1993). The incidence of IDDM in this age

group is expected to rise even higher since the maximum effect of the

HiB vaccine on IDDM is not seen until 4 years after immunization.

********

http://vaccines.net/newpage41.htm

see graphs at webpage

http://vaccines.net/newpage6.htm

see graphs at webpage